secwatch.observer — SEC 8-K summary
======================================

Issuer:     PULSE BIOSCIENCES, INC. (PLSE)
CIK:        0001625101
Form:       8-K
Filed at:   2026-03-09T23:59:59+00:00
Accession:  0001437749-26-007283
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulse Biosciences reports 74% avg volume reduction in benign thyroid nodule ablation at 15-22 months
--------------------------------------------------------------------------------

- 21 patients monitored 15-22 months; average 74% volume reduction of benign thyroid nodules with no regrowth.
- 100% of patients highly satisfied with cosmetic appearance; 95% highly satisfied overall; no serious adverse events.
- Data presented by Prof. Stefano Spiezia at North American Society for Interventional Thyroidology 2026 meeting.
- CEO Paul LaViolette said non-cardiac nsPFA plans will be clarified in second half of 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926007283/0001437749-26-007283-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1625101/000143774926007283/plse20260306_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-007283

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer